Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2024

Genmab — Februar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • B Offline
    B Offline
    bikube
    wrote on sidst redigeret af
    #46

    havana - Jeg ville aldrig sælge alt på en gang, sælg evt. 20% hver anden måned, hvis du sælger alt nu, misser du måske et stort overskud.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #47

      Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastisk Cervical Cancer https://www.proinvestor.com/investornyt/1111713/tisotumab-vedotin-marketing-authorization-application-validated-by-european-medicines-agency-for-treatment-of-recurrent-or-meta

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #48

        Genmab: EMA vil behandle ansøgning om godkendelse af middel mod livmoderhalskræft https://www.proinvestor.com/investornyt/1111730/genmab-ema-vil-behandle-ansogning-om-godkendelse-af-middel-mod-livmoderhalskraeft

        1 Reply Last reply
        0
        • V Offline
          V Offline
          Vitus
          wrote on sidst redigeret af
          #49

          Reagerer overhovedet ikke på det…..men der er jo heller ikke kommet noget penge i kassen på det endnu…

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #50

            Abbvie reports Epkinly Q4 '23 US12 Intl 5 Total 17, Full year '23 : 26 / 5 / 31 . U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories. This compares to Q3 Genmab comment around $22 million in net sales for the quarter and $28 million year-to-date.

            17

            1 Reply Last reply
            0
            • V Offline
              V Offline
              Vitus
              wrote on sidst redigeret af
              #51

              Nå, den kunne godt reagere 😞

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #52

                So the US number we have to double I think, the International i am not sure. But since it is such a small number it won't matter much. So it is total 52 + 10 = 62 or 52 + 5 = 57 total (T)Epkinly for the year

                1 Reply Last reply
                0
                • SolsenS Offline
                  SolsenS Offline
                  Solsen
                  wrote on sidst redigeret af
                  #53

                  Wasnt the deal that Genmab report US sales ?

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #54

                    This collaboration will provide for the joint development and commercialization of the three bispecific antibody therapeutic candidates. For epcoritamab, the companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Genmab will book net sales in the U.S. and Japan and receive tiered royalties on remaining global sales.

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #55

                      yes , so that is why they say 'U.S. revenues reflect profit sharing.', so i assume we need to double those. That makes sense also with last quarter; they reported 14 and Genmab said total was 28 (no international sales yet then)

                      1 Reply Last reply
                      0
                      • SolsenS Offline
                        SolsenS Offline
                        Solsen
                        wrote on sidst redigeret af
                        #56

                        You are right off cause 🙂

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #57

                          Maybe the 5 for international is full international and they pay Genmab 2.5 from that. dunno.

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #58

                            Until we get the Japan figures we vant calculate. But as you say - doesnt matter. On the other hand its hard to judge if its a success. So early in process.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #59

                              New trial - Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy -by 'Academic and Community Cancer Research United' https://clinicaltrials.gov/study/NCT06238648

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #60

                                useless fun fact: META is up by ~20% or $200bn today. If that money would have gone to Genmab it would be trading at around dkk23.000 now 🙂

                                1 Reply Last reply
                                0
                                • J Offline
                                  J Offline
                                  JKY_VH
                                  wrote on sidst redigeret af
                                  #61

                                  that would never happen, the board would cash in all the money;-)

                                  1 Reply Last reply
                                  0
                                  • H Offline
                                    H Offline
                                    henrik48
                                    wrote on sidst redigeret af
                                    #62

                                    Det giver et godt perspektiv om at 70% af alle aktie-værdier er på Wall street…

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bibob
                                      wrote on sidst redigeret af
                                      #63

                                      God morgen. 🙂

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #64

                                        Godmorgen 🙂

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Stroka
                                          wrote on sidst redigeret af
                                          #65

                                          God morgen 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper